^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abiraterone acetate

    i
    Other names: CB 7630, JNJ-212082, CB-7630, CB7630, BR9004
    Company:
    Generic mfg.
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    1d
    Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers. (PubMed, EClinicalMedicine)
    Of all trials, only MAGNITUDE, evaluating niraparib and abiraterone, led to aligned conclusions from both the EMA and FDA, as its design effectively identified the subgroup most likely to benefit. Currently, there is a need for harmonisation in biomarker-driven trial designs and the definition of homologous recombination repair deficiency (HRD). Access to biomarker and clinical data from all PARP-inhibitor trials would allow researchers to clarify the impact of different HRR mutations on outcomes.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Zejula (niraparib) • abiraterone acetate
    1d
    PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis. (PubMed, Eur Urol Open Sci)
    However, for BRCA-mutated mCRPC, olaparib combined with abiraterone improved PFS (HR = 0.61, 95% CrI = 0.41-0.91) and OS (HR = 0.41, 95% CrI = 0.21-0.80) significantly. For patients with changes in other related DNA repair genes (but not BRCA), olaparib alone was an effective treatment. This information may assist doctors and patients in choosing the most suitable treatment based on the cancer's genetic characteristics.
    Retrospective data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    5d
    PSMAndARPI: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=420 --> 7
    Enrollment closed • Enrollment change
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    5d
    InavoPC: A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FoundationOne® CDx
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Itovebi (inavolisib)
    7d
    A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=750, Recruiting, Amgen | Trial primary completion date: Aug 2028 --> Jan 2030
    Trial primary completion date
    |
    docetaxel • abiraterone acetate • cabazitaxel • xaluritamig (AMG 509)
    11d
    MEVPRO-2: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (clinicaltrials.gov)
    P3, N=900, Recruiting, Pfizer | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • mevrometostat (PF-06821497)
    11d
    A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (clinicaltrials.gov)
    P3, N=600, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • mevrometostat (PF-06821497)
    13d
    Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Rutgers, The State University of New Jersey | Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • prednisone • apalutamide
    20d
    A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=370, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    Xtandi (enzalutamide) • abiraterone acetate
    20d
    AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P3, N=940, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2028 --> Feb 2028
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)
    21d
    A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer. (PubMed, South Asian J Cancer)
    Adverse events were observed in 5 (14.3%) patients, but there were no deaths related to abiraterone. This real-world study provides evidence that generic abiraterone (Abiratred) is both well-tolerated and effective for patients with advanced or metastatic prostate cancer, making it a promising option in real-world clinical settings.
    Retrospective data • Journal • Real-world evidence
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
    |
    abiraterone acetate